THE GLOBAL NEUROSTIMULATION DEVICE MARKET FORECAST 2017-2025

July 2017 | 162 pages | ID: GCB6D8D2542EN
Inkwood Research

Abstracts

KEY FINDINGS

The global neurostimulation device market which was worth $1902 million in 2016 is anticipated to grow at a CAGR of 8.67% during the forecast period of 2017-2025. Its net worth is estimated to rise up to $4004 million by the end of 2025. The fact that these devices aid in the therapeutic activation for many neurological diseases is majorly driving the market. Other factors include:

• High occurrence of diseases
• Second-line of treatment
• Increased populace of elderly people
• Developments in technology

MARKET INSIGHTS

The global neurostimulation device market can be segmented on the basis of the type of system and by the application type. The type of systems include:

• Global SCS system market
• Global DBS system market
• Global SNS system market
• Global VNS system market
• Others

The application of the neurostimulation devices can be seen in:

• Pain management market
• Epilepsy market
• Essential tremor market
• Urinary and fecal incontinence market
• Depression market
• Dystonia market
• Gastroparesis market
• Parkinson's disease market

Albeit such wide range of applications, safety concerns remain to be one of the major market challenges. Patients might be at a risk of contracting infections at the time of implantation or may face issues if they are in contact with or near to electromagnetic radiation and electrical and gas-powered appliances. Also, the malfunction of implanted device might go unnoticed by the patient leading to higher risks.

REGIONAL INSIGHTS

Geographically, the market can be divided into 4 major regions:

• North America - U.S. & Canada
• Asia-Pacific – China, India, Japan, Australia, Rest of APAC
• Europe - UK, France, Germany, Spain, and Rest of Europe
• Rest of World

The Asia-Pacific market is predicted to show the fastest growth over the forecast period. Factors like a large patient base and the rising investments in healthcare sectors in countries like China and Japan are proving conducive for the market growth in this region. At present, however, the North America region is leading the market scene. The United States is a major revenue contributor to the global neurostimulation device market. The North American region is expected to continue this dominance and hold the highest share by 2025 in the global market. The market is wildly attracting investors from all over the globe because of profitable aspects like advances in technology and the US government's increased focus on improving patient safety and procedure efficiency by using neurostimulation devices

COMPETITIVE INSIGHTS

St. Jude Medical is a global medical device manufacturer that develops medical technology, products, and services for the treatment of neurological, chronic pain, and cardiac patients. Another company, Boston Scientific caters to high-quality medical devices used in the treatment of a large number of medical conditions. Medtronic Inc. manufactures and sells device-centered medicinal treatments globally along with assembling intra-operative imaging systems and image-guided surgery. It also offers web-based therapy management software solutions. The other major players in the market include Aleva Neurotherapeutics SA, Cogentix Medical Inc, Depuy Synthes Companies, Dr. Langer Medical GMBH, EBS Technologies Gmbh, Intrapace Inc, Neurological Surgery PC, Neuronetics Inc, Nevro Corp, and the Magstim Company Limited.

Contents

1. RESEARCH SCOPE

1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

2.1. SOURCES OF DATA
  2.1.1. SECONDARY DATA
  2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

3.1. MARKET SUMMARY
3.2. KEY FINDINGS
  3.2.1. NEUROSTIMULATION DEVICE MARKET IS GROWING AT A MODERATE RATE
  3.2.2. UNITED STATES IS THE MAJOR REVENUE CONTRIBUTOR
  3.2.3. AID IN THE THERAPEUTIC ACTIVATE

4. MARKET DETERMINANTS

4.1. MARKET DRIVERS
  4.1.1. HIGH OCCURRENCE OF DISEASES
  4.1.2. DEVELOPMENTS IN TECHNOLOGY
  4.1.3. INCREASED POPULACE OF ELDERLY PEOPLE
  4.1.4. SECOND-LINE OF TREATMENT
4.2. RESTRAINTS
  4.2.1. HIGH VALUE OF SCS DEVICE AND EARLY TREATMENT
  4.2.2. POSSIBLE SIDE EFFECTS OF SCS THERAPY AND COMPLICATIONS
  4.2.3. ANONYMOUS APPLIANCE OF SCS THERAPY
4.3. OPPORTUNITIES
  4.3.1. DEVELOPMENT OF INDICATION FOR SCS
  4.3.2. REQUIREMENT FOR MRI DEVICES
  4.3.3. GROWING OCCURRENCE OF CHRONIC DISCOMFORT
4.4. MARKET CHALLENGES
  4.4.1. OBTAINABILITY OF ALTERNATIVE THERAPY
  4.4.2. HIGH PRICE OF TREATMENT
  4.4.3. SAFETY CONCERNS

5. MARKET SEGMENTATION

5.1. MARKET BY SYSTEM 2017-2025
  5.1.1. GLOBAL SCS SYSTEM MARKET
  5.1.2. GLOBAL DBS SYSTEM MARKET
  5.1.3. GLOBAL SNS SYSTEM MARKET
  5.1.4. GLOBAL VNS SYSTEM MARKET
  5.1.5. OTHERS
5.2. MARKET BY APPLICATION 2017-2025
  5.2.1. PAIN MANAGEMENT MARKET
  5.2.2. EPILEPSY MARKET
  5.2.3. ESSENTIAL TREMOR MARKET
  5.2.4. URINARY AND FECAL INCONTINENCE MARKET
  5.2.5. DEPRESSION MARKET
  5.2.6. DYSTONIA MARKET
  5.2.7. GASTROPARESIS MARKET
  5.2.8. PARKINSON'S DISEASE MARKET

6. KEY ANALYTICS

6.1. PORTERS 5 FORCES ANALYSIS
  6.1.1. THREAT OF NEW ENTRANTS
  6.1.2. THREAT OF SUBSTITUTES
  6.1.3. BARGAINING POWER OF SUPPLIERS
  6.1.4. BARGAINING POWER OF BUYERS
  6.1.5. THREAT OF RIVALRY
6.2. ESTIMATION ANALYSIS
  6.2.1. INCREASING PREVALENCE OF MENTAL HEALTH PROBLEME
  6.2.2. RISING HEALTHCARE EXPENDITURE ACROSS THE GLOBE
  6.2.3. RISING GERIATRIC POPULATION
6.3. VALUE CHAIN ANALYSIS
  6.3.1. FOR DRUGS
    6.3.1.1. MANUFACTURERS
    6.3.1.2. DISTRIBUTORS
    6.3.1.3. RETAILERS
    6.3.1.4. END-USERS
  6.3.2. FOR DEVICES
    6.3.2.1. MANUFACTURERS
    6.3.2.2. DISTRIBUTORS
    6.3.2.3. END-USERS
6.4. OPPORTUNITY MATRIX
6.5. VENDOR LANDSCAPE

7. GEOGRAPHICAL ANALYSIS

7.1. NORTH AMERICA
  7.1.1. UNITED STATES
  7.1.2. CANADA
7.2. EUROPE
  7.2.1. UNITED KINGDOM
  7.2.2. FRANCE
  7.2.3. GERMANY
  7.2.4. SPAIN
  7.2.5. REST OF EUROP
7.3. ASIA-PACIFIC
  7.3.1. INDIA
  7.3.2. CHINA
  7.3.3. JAPAN
  7.3.4. AUSTRALIA
  7.3.5. REST OF APAC
7.4. REST OF WORLD

8. COMPANY PROFILES

8.1. ALEVA NEUROTHERAPEUTICS SA
8.2. BOSTON SCIENTIFIC CORPORATION
8.3. COGENTIX MEDICAL INC
8.4. CYBERONICS INC
8.5. DEPUY SYNTHES COMPANIES
8.6. DR. LANGER MEDICAL GMBH
8.7. EBS TECHNOLOGIES GMBH
8.8. INTRAPACE INC
8.9. MEDTRONIC PLC
8.10. NEUROLOGICAL SURGERY PC
8.11. NEURONETICS INC
8.12. NEVRO CORP.
8.13. ST. JUDE MEDICAL, INC.
8.14. THE MAGSTIM COMPANY LIMITED

TABLE LIST

TABLE 1 GLOBAL NEUROSTIMULATION MARKET BY REGION 2017-2025($ MILLION)
TABLE 2 GLOBAL SYSTEM MARKET 2017-2025 ($ MILLIONS)
TABLE 3 GLOBAL NEUROSTIMULATION MARKET, BY APPLICATION 2017-2025 ($ MILLIONS)
TABLE 4 GLOBAL NEUTRACEUTICAL DEVICE MARKET, BY REGION 2017-2025 ($ MILLION)
TABLE 5 CONDITION TREATED BY NEUROSTIMULATION DEVICES IN US
TABLE 6 NORTH AMERICA NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 7 EUROPE NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
TABLE 8 ASIA PACIFIC NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)

FIGURE LIST

FIGURE 1 GLOBAL NEUROSTIMULATION MARKET 2017-2025($ MILLION)
FIGURE 2 GLOBAL SCS SYSTEM MARKET 2017-2025 ($ MILLIONS)
FIGURE 3 GLOBAL DBS SYSTEM MARKET 2017-2025 ($ MILLIONS)
FIGURE 4 GLOBAL SNS SYSTEM MARKET 2017-2025 ($ MILLIONS)
FIGURE 5 GLOBAL VNS SYSTEM MARKET 2017-2025 ($ MILLIONS)
FIGURE 6 GLOBAL OTHER SYSTEM MARKET 2017-2025 ($ MILLIONS)
FIGURE 7 GLOBAL PAIN MANAGEMENT MARKET 2017-2025 ($ MILLIONS)
FIGURE 8 GLOBAL EPILEPSY MARKET 2017-2025 ($ MILLIONS)
FIGURE 9 GLOBAL ESSENTIAL TREMOR MARKET 2017-2025 ($ MILLIONS)
FIGURE 10 GLOBAL URINARY AND FECAL INCONTINENCE MARKET 2017-2025 ($ MILLIONS)
FIGURE 11 GLOBAL DEPRESSION MARKET 2017-2025 ($ MILLIONS)
FIGURE 12 GLOBAL DYSTONIA MARKET 2017-2025 ($ MILLIONS)
FIGURE 13 GLOBAL GASTROPARESIS MARKET 2017-2025 ($ MILLIONS)
FIGURE 14 GLOBAL PARKINSON'S DISEASE MARKET 2017-2025 ($ MILLIONS)
FIGURE 15 PREVALENCE OF MENTAL HEALTH DISORDERS ACROSS THE GLOBE BETWEEN PERIOD 2012 AND 2020 (MILLION)
FIGURE 16 RISING GERIATRIC POPULATION ACROSS THE GLOBE FOR PERIOD 2014-2020 (MILLION)
FIGURE 17 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
FIGURE 18 UNITED STATES NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 19 CANADA NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 20 UNITED KINGDOM NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 21 FRANCE NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 22 GERMANY NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 23 SPAIN NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 24 REST OF EUROPE NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 25 INDIA NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 26 CHINA NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 27 JAPAN NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 28 AUSTRALIA NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 29 REST OF APAC NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)
FIGURE 30 REST OFWORLD NEUTRACEUTICAL DEVICE MARKET 2017-2025 ($ MILLION)